Protalix BioTherapeutics,
Inc. (NYSE: PLX) confirms, in response to inquiries received
this morning and a report appearing in the Israeli press, that the company has
engaged Citigroup to assist it in reviewing a broad array of product
partnering, technology sharing and other strategic alternatives. There is no
assurance that Protalix will undertake any such strategic alternative.

Protalix will not comment further on this initiative unless future events
would make doing so appropriate.